2015 Fiscal Year Final Research Report
The molecular mechanism of prostate cancer chemo-prevention agents with androgen receptor.
| Project/Area Number |
25462484
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
Akira Yokomizo 九州大学, 医学(系)研究科(研究院), 准教授 (60346781)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Keywords | 前立腺癌 / 化学予防 / 分子生物学 |
|---|
| Outline of Final Research Achievements |
To reveal the molecular mechanisms of chemoprevention of prostate cancer, we focused on aspirin, celecoxib and equol (isoflavone). We identified that prostaglandin receptor EP3 mediates growth inhibitory effect of aspirin through androgen receptor and contributes to castration resistance in prostate cancer cells. Furthermore, EP2 signaling mediates suppressive effects of celecoxib on androgen receptor expression and cell proliferation in prostate cancer. Finally, equol augments Skp2-mediated androgen receptor degradation. These findings will contribute to chemoprevention for prostate cancer.
|
| Free Research Field |
泌尿器科学
|
